

Identification of a Potent and Selective Cannabinoid CB₁ Receptor Antagonist from *Auxarthron reticulatum*

Mahmoud Fahmi Elsebai,^{†,||} Viktor Rempel,[§] Gregor Schnakenburg,[‡] Stefan Kehraus,[†] Christa E. Müller,^{*,§} and Gabriele M. König^{*,†}

[†]Institute for Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany

[‡]Institute of Inorganic Chemistry, Department of X-ray Crystallography, University of Bonn, 53121 Bonn, Germany


[§]Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, 53121 Bonn, Germany

^{||}Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Egypt

S Supporting Information

ABSTRACT: The fungus *Auxarthron reticulatum* derived from the marine sponge *Ircinia variabilis* produced the diketopiperazine alkaloid amaumomine (1) and the quinolinone methyl-penicinoline (2). Compound 2 is identical to the reported methyl-marinamide, whose structure is herewith revised. In radioligand binding studies at human cannabinoid CB₁ and CB₂ receptors recombinantly expressed in Chinese hamster ovary (CHO) cells, amaumomine (1) was found to exhibit high affinity and selectivity for the CB₁ receptor ($K_i = 178$ nM). The compound was shown to be a neutral CB₁ antagonist with a K_b value of 66.6 nM determined in cAMP assays. Compound 2 exhibited only weak or no effects at CB receptors. To the best of our knowledge, compound 1 is the first fungal natural product that shows affinity for cannabinoid CB₁ receptors. Because of its high antagonistic potency and selectivity, it may have potential for use as a drug and/or serve as a lead structure for drug development.

KEYWORDS: *Auxarthron reticulatum*, amaumomine, cannabinoid receptors, CB₁, CB₂, natural products



Cannabinoid receptors are located in the cell membrane and belong to the G protein-coupled receptor (GPCR) superfamily.¹ They are divided into two distinct subtypes designated CB₁ and CB₂, both of which are G_i protein-coupled mediating inhibition of adenylate cyclase, and thus, their activation results in reduced intracellular cAMP levels.² The CB₁ receptor is expressed in the central nervous system (CNS) in high density but also is present in peripheral tissues, including the lungs, liver, kidneys, and adipocytes.³ CB₁ activation mediates analgesia, stimulation of appetite, and euphoria, among other effects. CB₁ antagonists show appetite-suppressing and antischizophrenic properties.³ The CB₂ receptor is mainly present in organs and cells of the immune system including spleen, tonsils, and thymus, and its activation results in analgesic and anti-inflammatory effects.^{3,4}

Regarding the origin of the ligands of cannabinoid receptors, they can be classified into three groups: (1) endocannabinoids, such as *N*-arachidonylethanolamine, which are found in the mammalian nervous and immune system;⁵ (2) phytocannabinoids, such as Δ^9 -tetrahydrocannabinol (Δ^9 -THC), which are produced by the plant *Cannabis sativa*;⁶ and (3) synthetic cannabinoids such as the agonist nabilone, a synthetic analogue of Δ^9 -THC, and the antagonist rimonabant, which is synthetically produced. Nabilone (Cesamet) is therapeutically used for the suppression of chemotherapy-induced nausea and vomiting,⁷ for the treatment of neuropathic pain, and for the therapy of anorexia in patients with AIDS.³ Further indications include

chronic pain, fibromyalgia, and multiple sclerosis.³ CB₁ receptor antagonists are potential drugs for the treatment of schizophrenia, especially for treating the negative symptoms of the disease, and for the therapy of drug and alcohol addiction.³ Another indication for CB₁ receptor antagonists is the treatment of obesity, due to an appetite-suppressing effect mediated via central CB₁ receptors in the hypothalamus. Besides weight loss, a reduction in HbA_{1c} and triglyceride levels and an increase in high-density lipoprotein levels can be observed. Investigations have shown that these metabolic improvements are based on peripheral CB₁ receptor blockade. Thus, peripherally acting CB₁ receptor antagonists without CNS penetration would be promising drugs for the treatment of metabolic disorders associated with abdominal obesity, as they would be devoid of side effects caused by central CB₁ receptor activation, for example, depression and anxiety.^{3,4,8} CB₂ receptor inverse agonists/antagonists are potential drugs for the treatment of osteoporosis and were also shown to have beneficial effects in animal models of dermatitis.^{3,7} In the present study, we isolated compounds 1 and 2 from the marine sponge-derived fungus *Auxarthron reticulatum* and investigated the natural products for their interaction with CB receptors.

Received: July 29, 2011

Accepted: September 17, 2011

Published: September 17, 2011




Figure 1. Structures of amauromine (1) and methyl-penicinoline (2).

The fungal metabolite **1** is a dipeptide composed of two modified tryptophan units, which are cyclized forming a central diketopiperazine ring. Compound **1** is further characterized by the presence of two prenyl moieties, which are attached to the core structure through “reversed prenylation” (Figure 1). The molecular formula of compound **1** was deduced by accurate mass measurement [high-resolution electrospray ionization mass spectrometry (HRESIMS), $m/z = 509.2911 [M + H]^+$] to be $C_{32}H_{36}N_4O_2$. The NMR spectroscopic data showed only resonances for $C_{16}H_{18}$, and thus, it was concluded that a homodimeric structure was present and that each resonance signal in the 1H and ^{13}C NMR spectra represented at least two magnetically equivalent nuclei. Indeed, compound **1** is characterized by the presence of a C2-axis of symmetry (Supporting Information, Figure S2 and Table S3).

Because several stereoisomers of compound **1** are possible, it is difficult to delineate the absolute configuration of the molecule. Thus, for the determination of the absolute configuration, acid hydrolysis was performed followed by chiral HPLC chromatography (Supporting Information, Figure S14). This resulted in the detection of L-tryptophan indicating the *S*-configuration of the α -carbon atom of compound **1** (C-11/11'). Our data therefore showed that compound **1** is the alkaloid amauromine^{9–11} (=nigrifortine¹²). Compound **1** was previously investigated for its pharmacological effects and reported to be a vasodilator acting as a calcium entry blocker.^{9–11}

HRESIMS analysis of compound **2** (Figure 1) yielded the molecular formula $C_{15}H_{12}N_2O_3$ with 11 degrees of unsaturation. This molecular formula was supported by 1H and ^{13}C NMR spectra (Supporting Information, Figure S4 and Table S5), which showed resonance signals for two carbonyl groups (δ_c 173.8 for C-14 and 167.8 for C-16), five unsaturated quaternary carbon atoms (δ_c 123.0 for C-5, 140.9 for C-6, 139.7 for C-8, 124.3 for C-13, and 113.6 for C-15), seven unsaturated methine carbon atoms ($\delta_{H/C}$ 6.47/112.1 for CH-1, 6.25/110.1 for CH-2, 7.13/122.8 for CH-3, 7.66/118.7 for CH-9, 7.70/132.6 for CH-10, 7.36/123.9 for CH-11, and 8.07/124.9 for CH-12), and one methoxyl group ($\delta_{H/c}$ 3.67/52.1 for CH_3 -17). In addition, in the 1H and ^{13}C NMR spectra, there are two downfield shifted resonances at δ_H 11.63 and 11.70, which were determined to arise from NH-4 and NH-7, respectively. The downfield shift may be explained by intermolecular hydrogen bonds of the NH




Figure 2. Comparison of the structure of amauromine (1) with that of the CB₁ antagonist/inverse agonist rimonabant. Essential structural features (carbonyl group, lipophilic, and aromatic residues) of rimonabant and corresponding features in amauromine are circled by dashed lines.

groups with the carbonyl group at C-14 as seen in the X-ray derived structure (Supporting Information, Figure S1).

The methine carbons CH-9 to CH-12 are connected due to the mutual cross-peak correlations in both 1H – 1H correlation spectroscopy (COSY) and 1H – ^{13}C heteronuclear multiple bond correlation (HMBC) spectra (Supporting Information, Figure S6). They are also bound to the quaternary aromatic carbons C-13 and C-8, as confirmed by 1H – ^{13}C HMBC correlations from H-9 and from H-11 to C-13 and from H-10 and H-12 to C-8. Compound **2** is thus an ortho-disubstituted benzene derivative. C-13 is attached to the carbonyl carbon C-14 due to the 1H – ^{13}C HMBC correlation from H-12 to C-14, and C-8 is attached to NH-7 due to 1H – ^{13}C HMBC correlations from NH-7 to both C-9 and C-13. Also, in the 1H – ^{13}C HMBC spectrum, NH-7 exhibits correlations to C-6 and C-15, which results in a γ -pyridone ring including carbons C-8, C-13, and C-14. Such an arrangement forms a 4-quinolinone ring, which is substituted at C-15 and C-6. The substitution at C-15 is a methyl carboxylate residue due to the 1H – ^{13}C HMBC cross-peak correlations from the methoxyl group CH_3 -17 to both C-15 and C-16, whereas the substitution at C-6 is an α -pyrrolyl moiety. The latter was proven from the data acquired in 1H – 1H COSY and 1H – ^{13}C HMBC experiments. Thus, H-1 to H-3 are forming a spin system, which together with the key HMBC correlations between them and the carbons C-1 to C-5 implies the presence of a pyrrol ring. The nuclear Overhauser effect spectroscopy correlation of NH-4 to H-3 confirmed this conclusion. The pyrrol ring is linked to the quinolinone nucleus at C-6 due to the 1H – ^{13}C HMBC cross-peak correlation from NH-7 to C-5. X-ray diffraction analysis allowed the structure of **2** to be unambiguously established. It is a structurally unique 4-quinolinone, linked to a pyrrole ring on one side and a methyl carboxylic acid ester moiety at the other side.

A similar compound, that is, methyl-marinamide,¹³ which was described as an isoquinolinone analogue of **2**, was already described in the literature (Supporting Information, Figure S13). Surprisingly, this compound has the same NMR chemical shifts as compound **2**, and thus, we assume that the structures of methyl-marinamide and also of the related marinamide are wrong. This is further confirmed by the recently reported compound penicinoline,¹⁴ which shows the same structural features as compound **2**, except that it is not methylated (i.e., CH_3 -17). Penicinoline, according to our analysis, is identical to marinamide.

Because of the structural similarity between amauromine and the CB₁ antagonist rimonabant (Figure 2), we investigated the isolated natural products **1** and **2** in radioligand binding studies¹⁵ at human cannabinoid CB₁ and CB₂ receptors recombinantly expressed in Chinese hamster ovary (CHO-K1) cells obtained by




Figure 3. Concentration-dependent inhibition of specific [^3H]CP55,940 binding by amauromine at membrane preparations of CHO cells recombinantly expressing human CB $_1$ receptors. Data points represent means \pm SEMs of three independent experiments, performed in duplicate.




Figure 4. Concentration-dependent inhibition of forskolin (10 μM)-induced cAMP accumulation by the CB agonist CP55,940 in CHO cells recombinantly expressing the human CB $_1$ receptor in the absence and in the presence of amauromine (300 nM). Data points are means \pm SEMs of three independent experiments performed in duplicate. A K_B value of 66.6 ± 57.0 nM was determined for amauromine (**1**).

retroviral transfection (Hinz, S.; Karcz, T.; Müller, C. E. Unpublished results). Compound **1** showed very high affinity for CB $_1$ receptors exhibiting a K_i value of 178 nM (Figure 3), while it did not show any affinity at a high concentration of 10 μM at CB $_2$ receptors (Figure S7, Supporting Information). In functional assays measuring forskolin-induced cAMP accumulation in CHO cells,¹⁶ expressing the human CB $_1$ receptor amauromine (**1**) did not show agonistic effects (Figure S8, Supporting Information). However, compound **1** (300 nM) led to a significant rightward shift of the concentration–response curve for the potent CB receptor agonist CP55,940 in inhibiting forskolin-induced cAMP accumulation at the G $_i$ protein-coupled CB $_1$ receptor (Figure 4). A K_b value of 66.6 nM was determined for **1**. To the best of our knowledge, compound **1** is the first compound of fungal origin to show affinity toward cannabinoid receptors. Compound **2** exhibited only weak affinity for CB $_1$ and CB $_2$ receptors (Figure S7, Supporting Information).

In light of our results, it is interesting to note that many synthetic indole derivatives have already been examined with regard to their affinity for CB receptors.^{7,17–19} In a number of studies, indole derivatives were identified that exhibit potent agonistic, cannabimimetic effects on CB $_2$, but only weak or no affinity for CB $_1$ receptors. In contrast to those previous results, compound **1** functions as a selective antagonist at the CB $_1$ receptor. Only very recently, the first natural alkaloids with

CB $_1$ -antagonistic activity isolated from the plant *Voacanga africana* were described.¹⁹

Functional studies indicate that compound **1** appears to be a neutral competitive antagonist, as no increased cAMP levels could be detected in cAMP accumulation assays. There is evidence that neutral antagonists may be preferable over inverse agonists when used as drugs, because they do not alter basic activity arising from spontaneous receptor signaling and, thus, may cause less side effects. For example, it has been reported that the neutral CB $_1$ receptor antagonist AM4113 had effects comparable to that of the CB $_1$ inverse agonist AM251 regarding food intake and food-reinforcement behavior in rats, but in contrast to AM251, it failed to induce nausea.^{7,20} Furthermore, neutral antagonists are useful experimental tools as they show no effect on their own and, thus, will facilitate the investigation of the physiological role of the endocannabinoid system.^{7,21}

Recent studies have emphasized important roles for the endocannabinoid system, that is, receptors and endogenous ligands, in many pathophysiological processes. Therefore, CB $_1$ and CB $_2$ receptors are regarded as important drug targets for a number of common diseases for which new drugs are urgently needed, including Parkinson's and Alzheimer's disease, major depression, inflammation, neuropathic pain, and metabolic syndrome.²² The identification of the structurally novel cannabinoid receptor ligand amauromine (compound **1**) provides an opportunity for the development of a new chemical class of therapeutic agents for the treatment of a number of disorders involving CB $_1$ cannabinoid receptors.

■ ASSOCIATED CONTENT

S Supporting Information. Full experimental procedures, complete crystallographic data for compound **2**, compound characterization for compounds **1** and **2**, ^1H and ^{13}C NMR spectra for compounds **1** and **2**, purity data of compound **1**, diagrams of affinities of compounds **1** and **2** toward CB receptors, and results for compound **1** in cAMP accumulation assays at CB $_1$ receptor. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 0049(228)73-2301. E-mail: christa.mueller@uni-bonn.de (C.E.M.). Tel: 0049(228)73-3194. E-mail: g.koenig@uni-bonn.de (G.M.K.).

Funding Sources

Financial support was provided by the Egyptian Government (M.F.E.) and the BMBF (G.M.K., project no. 03F0415A). Funding by the BMBF (project no. 01EW0911) in the frame of ERA-NET NEURON is gratefully acknowledged (C.E.M.).

■ DEDICATION

This paper is dedicated to Professors Hassan Elrady A. Saad, Sahar Gedara, and Ahmed Gohar.

■ REFERENCES

(1) Graham, E. S.; Ashton, J. C.; Glass, M. Cannabinoid receptors: A brief history and “what’s hot”. *Front. Biosci.* **2009**, *14*, 944–957.

- (2) Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* **1990**, *346*, 561–564.
- (3) Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* **2006**, *58*, 389–462.
- (4) Racz, L.; Nadal, X.; Alferink, J.; Banos, J. E.; Rehnelt, J.; Martin, M.; Pintado, B.; Gutierrez-Adan, A.; Sanguino, E.; Manzanares, J.; Zimmer, A.; Maldonado, R. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. *J. Neurosci.* **2008**, *28*, 12125–12135.
- (5) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **1992**, *258*, 1946–1949.
- (6) Fusar-Poli, P.; Crippa, J. A.; Bhattacharyya, S.; Borgwardt, S. J.; Allen, P.; Martin-Santos, R.; Seal, M.; Surguladze, S. A.; O'Carroll, C.; Atakan, Z.; Zuardi, A. W.; McGuire, P. K. Distinct effects of Δ^9 -tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. *Arch. Gen. Psychiatry* **2009**, *66*, 95–105.
- (7) Pertwee, R. G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. *Curr. Med. Chem.* **2010**, *17*, 1360–1381.
- (8) Scheen, A. J.; Paquot, N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. *Best. Pract. Res. Clin. Endocrinol. Metab.* **2009**, *23*, 103–116.
- (9) Takase, S.; Kawai, Y.; Uchida, I.; Tanaka, H.; Aoki, H. Structure of amauromine, a new alkaloid with vasodilating activity produced by *Amauroascus* sp. *Tetrahedron Lett.* **1984**, *25*, 4673–4676.
- (10) Takase, S.; Iwami, M.; Ando, T.; Okamoto, M.; Yoshida, K.; Horiai, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. Amauromine, a new vasodilator. Taxonomy, isolation and characterization. *J. Antibiot.* **1984**, *37*, 1320–1323.
- (11) Takase, S.; Kawai, Y.; Uchida, I.; Tanaka, H.; Aoki, H. Structure of amauromine, a new hypotensive vasodilator produced by *Amauroascus* sp. *Tetrahedron* **1985**, *41*, 3037–3048.
- (12) Laws, I.; Mantle, P. G. Nigrifortine, a diketopiperazine metabolite of *Penicillium nigricans*. *Phytochemistry* **1985**, *24*, 1395–1397.
- (13) Zhu, F.; Lin, Y. Marinamide, a novel alkaloid and its methyl ester produced by the application of mixed fermentation technique to two mangrove endophytic fungi from the South China Sea. *Chin. Sci. Bull.* **2006**, *51*, 1426–1430.
- (14) Shao, C.-L.; Wang, C.-Y.; Gu, Y.-C.; Wei, M.-Y.; Pan, J.-H.; Deng, D.-S.; She, Z.-G.; Lin, Y.-C. Penicoline, a new pyrrolyl 4-quinolinone alkaloid with an unprecedented ring system from an endophytic fungus *Penicillium* sp. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3284–3286.
- (15) Behrenswerth, A.; Volz, N.; Torang, J.; Hinz, S.; Bräse, S.; Müller, C. E. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. *Bioorg. Med. Chem.* **2009**, *17*, 2842–2851.
- (16) Drabczynska, A.; Yuzlenko, O.; Köse, M.; Paskaleva, M.; Schiedel, A. C.; Karolak-Wojciechowska, J.; Handzlik, J.; Karcz, T.; Kuder, K.; Müller, C. E.; Kiec-Kononowicz, K. Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurine-diones. *Eur. J. Med. Chem.* **2011**, *46*, 3590–3607.
- (17) Poso, A.; Huffman, J. W. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. *Br. J. Pharmacol.* **2008**, *153*, 335–346.
- (18) Huffman, J. W.; Zengin, G.; Wu, M.-J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L. S.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. *Bioorg. Med. Chem.* **2005**, *13*, 89–112.
- (19) Kitajima, M.; Iwai, M.; Kikura-Hanajiri, R.; Goda, Y.; Iida, M.; Yabushita, H.; Takayama, H. Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1962–1964.
- (20) Sink, K. S.; McLaughlin, P. J.; Wood, J. A.; Brown, C.; Fan, P.; Vemuri, V. K.; Peng, Y.; Olszewska, T.; Thakur, G. A.; Makriyannis, A.; Parker, L. A.; Salamone, J. D. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. *Neuropsychopharmacology* **2008**, *33*, 946–955.
- (21) Wiley, J. L.; Breivogel, C. S.; Mahadevan, A.; Pertwee, R. G.; Cascio, M. G.; Bolognini, D.; Huffman, J. W.; Walentiny, D. M.; Vann, R. E.; Razdan, R. K.; Martin, B. R. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. *Eur. J. Pharmacol.* **2010**, *651*, 96–105.
- (22) Heimann, A. S.; Gomes, I.; Dale, C. S.; Pagano, R. L.; Gupta, A.; de Souza, L. L.; Luchessi, A. D.; Castro, L. M.; Giorgi, R.; Rioli, V.; Ferro, E. S.; Devi, L. A. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 20588–20593.